Gilead scores PrEP ap­proval for De­scovy — kick­ing off mar­ket­ing push be­fore Tru­va­da gener­ics swarm

The FDA has cleared Gilead’s De­scovy — a top pipeline drug it spent a pri­or­i­ty re­view vouch­er on — for HIV pre-ex­po­sure pro­phy­lax­is in a broad, but …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.